Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BioteBTMD -1.84%68 Debt-to-Equity is -1.93 as of Mar. 2026. GuruFocus rates BTMD with a GF Score™ of 68/100 and a GF Value™ of $3.06 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 557 Healthcare Providers & Services companies, Biote ranks worse than 179533.03% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Biote's Debt-to-Equity or its related term are showing as below:
BTMD'
s Debt-to-Equity Range Over the Past 10 Years
Min: -4.86 Med: -2.19 Max: 9.05
Current: -1.93
During the past 7 years, the highest Debt-to-Equity Ratio of Biote was 9.05. The lowest was -4.86. And the median was -2.19.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Biote Debt-to-Equity Related Terms
Biote Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Biote's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BTMD vs DCGO, PARK, PIII: Debt-to-Equity Comparison
For the Medical Care Facilities subindustry, Biote's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biote Debt-to-Equity vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Biote's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Biote's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biote (BTMD) has a Debt-to-Equity of -1.93 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Biote and its competitors. According to the industry distribution chart, Biote ranks #999999 out of 557 companies in the Healthcare Providers & Services industry.
Is Biote's Debt-to-Equity too high?
Biote's current Debt-to-Equity is -1.93. Based on the distribution chart, Biote ranks #999999 out of 557 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Biote has a GF Score™ of 68/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Biote's Debt-to-Equity compare to DCGO and PARK?
According to the Healthcare Providers & Services industry distribution chart, Biote ranks #999999 out of 557 companies for Debt-to-Equity. This places Biote in the lower half of its industry. The industry median Debt-to-Equity is 0.41. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Healthcare Providers & Services company?
The median Debt-to-Equity among Healthcare Providers & Services companies is 0.41, based on 557 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Biote and its competitors. For the Healthcare Providers & Services industry, the median Debt-to-Equity is 0.41 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Biote's current Debt-to-Equity is -1.93. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biote stock overvalued right now?
Based on GuruFocus' analysis, Biote (BTMD) is currently considered Significantly Undervalued. The stock's GF Value™ is $3.06, compared to a current price of $1.60 — trading 47.7% below its estimated fair value. The current Debt-to-Equity is -1.93. Biote's overall GF Score™ is 68/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Biote (BTMD), the current Debt-to-Equity is -1.93 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Biote (BTMD) Overvalued in 2026?
Based on GuruFocus' analysis, Biote stock appears to be undervalued.
The current stock price of $1.60 is trading 47.7% below its estimated GF Value™ of $3.06.
GuruFocus considers Biote to be Significantly Undervalued.
Key valuation signals for BTMD:
Debt-to-Equity: -1.93
GF Value™: $3.06 vs. price of $1.60 (47.7% below fair value)
No single metric tells the full story. See the BTMD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Biote Corp operates a growth practice-building business within the hormone optimization space. It provides the necessary components to enable Biote-certified practitioners to establish, build, and successfully implement a program designed to optimize hormone levels using personalized solutions for their patient populations. The company provides support to medical practitioners through training, practice development, and operational services to establish and manage hormone therapy centers. Its activities include educating practitioners on identifying and treating hormone-related conditions. The company generates revenues by charging the Biote-partnered clinics fees associated with the Biote Method and from the sale of Biote-branded dietary supplements.
68GF Score
Get the complete analysis for BTMD
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BTMD has been successfully added to your 
